Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1047 in Subjects With Malignant Solid Tumors
NCT05180474Phase 2Terminated
- Sponsor
- Genmab
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of GEN1047 in breast cancer, endometrial cancer (EC), ovarian cancer and 1 more, sponsored by Genmab. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 5 months and 1 more. Started Dec 2021; status: terminated.
02
Drugs
GEN1047
03
Conditions
breast cancerendometrial cancer (EC)ovarian cancersquamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05180474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180474.